ERAS Protocol Revolutionizes 3-Year Survival After Esophagectomy: Insights from Landmark Study

Understanding the ERAS Protocol in Esophageal Cancer Surgery

Esophagectomy, the surgical removal of the esophagus, is one of the most complex oncological procedures, often performed for esophageal cancer patients. Traditionally, this surgery is fraught with complications due to the extensive nature of the operation and the frailty of patients, who often suffer from malnutrition and other comorbidities. The Enhanced Recovery After Surgery (ERAS) protocol represents a multidisciplinary, evidence-based approach to optimize perioperative care and recovery. While its benefits are well documented in various surgical fields, its long-term impact on esophageal cancer outcomes remained unclear until recently.

Study Overview: Comparing ERAS with Standard Care

Researchers at Taichung Veterans General Hospital conducted a retrospective analysis of 124 patients who underwent elective esophagectomy between January 2017 and January 2022. The study aimed to compare 3-year survival rates and postoperative outcomes between patients managed with the ERAS protocol and those receiving conventional care.

• Patients treated before April 2019 received standard care; those afterward followed ERAS.

• Exclusions included cases with distant metastasis or concurrent surgeries.

• Key endpoints included 3-year overall survival, ICU/hospital length of stay, and complication rates.

• Statistical rigor was maintained via multivariate Cox regression and Kaplan–Meier survival analysis.

Key Findings: ERAS Delivers Significant Survival and Recovery Benefits

Improved Survival Rates

The 3-year overall survival rate in the ERAS group was dramatically higher (70.2%) compared to the control group (47.4%). Multivariate analysis confirmed the ERAS protocol as an independent positive prognostic factor (adjusted hazard ratio: 0.44, p=0.020). Notably, patients with preoperative hypoalbuminemia, advanced cancer stage, or age below 65 years experienced the greatest survival benefits.

Reduced Hospital and ICU Stays

Implementing ERAS led to shorter ICU stays (mean reduction of 2.3 days) and hospital stays (mean reduction of 4.9 days), indicating a faster postoperative recovery. Importantly, this acceleration in recovery did not result in higher complication rates; both groups had comparable rates of postoperative complications, with the ERAS group experiencing fewer pulmonary issues.

Enhanced Completion of Adjuvant Therapies

The ERAS group also had a 100% completion rate of adjuvant chemoradiotherapy among those who initiated it, compared to only 63.2% in the control group. This aligns with the emerging concept of "Return to Intended Oncologic Therapy" (RIOT), highlighting how timely recovery supports ongoing cancer treatments and may contribute to improved survival.

Implications and Limitations

The study’s results suggest that ERAS protocols can indirectly enhance long-term survival by enabling better tolerance for essential adjuvant therapies and reducing surgical stress. However, the retrospective design and limited sample size mean these findings should be validated in larger, prospective studies.

Key Takeaways:

• ERAS protocol significantly improves 3-year survival rates after esophagectomy.

• Shorter ICU and hospital stays are achieved without increasing complication rates.

• Greatest survival benefits observed in patients with low albumin, advanced cancer, or age <65.

• ERAS enhances completion rates of vital postoperative cancer therapies (RIOT effect).

Citation:

Chen S-J, Shen C-H, Chuang C-Y, Chang Y-T. Impact of the enhanced recovery after surgery (ERAS) protocol on 3-year survival and outcomes following esophagectomy: a retrospective cohort study of 124 patients. BMC Anesthesiology. 2025;25:256. https://doi.org/10.1186/s12871-025-03124-9